Simone Aleandri
Overview
Explore the profile of Simone Aleandri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eugster R, Orsi M, Buttitta G, Serafini N, Tiboni M, Casettari L, et al.
J Control Release
. 2024 Nov;
376:1025-1038.
PMID: 39489466
Drug delivery systems efficiently and safely administer therapeutic agents to specific body sites. Liposomes, spherical vesicles made of phospholipid bilayers, have become a powerful tool in this field, especially with...
2.
Xin L, Madarasz A, Ivan D, Weber F, Aleandri S, Luciani P, et al.
J Neuroinflammation
. 2024 Oct;
21(1):272.
PMID: 39444001
Accumulation of immune cells and proteins in the subarachnoid space (SAS) is found during multiple sclerosis and in the animal model experimental autoimmune encephalomyelitis (EAE). Whether the flow of cerebrospinal...
3.
Gazzi R, Gelli R, Eugster R, Buhr C, Schurch S, Mezzenga R, et al.
J Colloid Interface Sci
. 2024 Sep;
678(Pt C):595-607.
PMID: 39305627
Lipidic mesophase drug carriers have demonstrated the capacity to host and effectively deliver a wide range of active pharmaceutical ingredients, yet they have not been as extensively commercialized as other...
4.
Gazzi R, Gelli R, Aleandri S, Carone M, Luciani P
Wiley Interdiscip Rev Nanomed Nanobiotechnol
. 2024 Aug;
16(4):e1986.
PMID: 39140489
Due to its chronic nature and complex pathophysiology, inflammatory bowel disease (IBD) poses significant challenges for treatment. The long-term therapies for patients, often diagnosed between the ages of 20 and...
5.
Arenas Hoyos I, Helmer A, Yerly A, Lese I, Hirsiger S, Zhang L, et al.
Front Immunol
. 2024 Jun;
15:1387945.
PMID: 38887281
Introduction: The standard treatment for preventing rejection in vascularized composite allotransplantation (VCA) currently relies on systemic immunosuppression, which exposes the host to well-known side effects. Locally administered immunosuppression strategies have...
6.
Allegritti E, Giansanti L, Bordon G, Maggi M, Luciani P, Aleandri S
J Colloid Interface Sci
. 2024 Mar;
664:1031-1041.
PMID: 38521004
In this study, we explored the use of lipid mesophases (LMPs) as a biocompatible and biodegradable material for sustained drug delivery. Our hypothesis centered on leveraging the high surface-to-volume ratio...
7.
Dzhumashev D, Anton-Joseph S, Morel V, Timpanaro A, Bordon G, Piccand C, et al.
Eur J Pharm Biopharm
. 2023 Nov;
194:49-61.
PMID: 38029941
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. More effective and less toxic therapies are urgently needed for high-risk patients. Peptide-guided targeted drug delivery can increase the therapeutic...
8.
Eugster R, Ganguin A, Seidi A, Aleandri S, Luciani P
Drug Deliv Transl Res
. 2023 Nov;
14(6):1567-1581.
PMID: 38006449
The peritoneal cavity offers an attractive administration route for challenging-to-treat diseases, such as peritoneal carcinomatosis, post-surgical adhesions, and peritoneal fibrosis. Achieving a uniform and prolonged drug distribution throughout the entire...
9.
Skorup I, Valentino G, Aleandri S, Gelli R, Ganguin A, Felli E, et al.
Int J Pharm
. 2023 Oct;
646:123473.
PMID: 37788730
Liver fibrosis is a condition characterized by the accumulation of extracellular matrix (ECM) arising from the myofibroblastic transdifferentiation of hepatic stellate cells (HSCs) occurring as the natural response to liver...
10.
Bordon G, Ramakrishna S, Edalat S, Eugster R, Arcifa A, Vermathen M, et al.
J Colloid Interface Sci
. 2023 Jul;
650(Pt B):1659-1670.
PMID: 37494862
Liposomes show promise as biolubricants for damaged cartilage, but their small size results in low joint and cartilage retention. We developed a zinc ion-based liposomal drug delivery system for local...